Truist raises Globe Life stock price target to $185 on higher EPS outlook

The key signal here is not the modest earnings miss; it is that the multiple reset is being driven by higher forward EPS while the stock is already priced near peak levels. That combination tends to compress upside unless the company can keep out-earning estimates for several quarters in a row, because insurers at full valuation are punished less for stability than for any deceleration in growth.

Second-order, the earnings raise implies the market may be underappreciating how much of the rerating is already embedded. If the stock is now trading close to the new implied target multiple, the next leg likely depends on either continued estimate revisions or a broader rotation into defensive financials. Absent that, the name can drift sideways for months even if fundamentals remain fine.

The contrarian angle is that the “Buy” case may be more about quality and balance-sheet durability than near-term alpha. That makes GL attractive as a relative long only if the market is rewarding defensives and penalizing more cyclical financials; otherwise, the risk/reward from current levels is asymmetrically muted. The cleanest bearish catalyst would be any sign of claims normalization, slower premium growth, or a break in the upward EPS revision trend over the next 1-2 quarters.